<p>Nwam LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在阿斯利康制药 (NASDAQ:AZN - 免费报告) 的持股减少了 40.1%。该基金在此期间出售了 4,720 股后，持有该公司 7,036 股股票。Nwam LLC 在阿斯利康的持股在最近的报告期末价值为 535,000 美元。</p>
<ul>
<li>D-Wave 与量子竞争对手相比如何？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对该公司的持股。Vise Technologies Inc. 在第二季度购买了阿斯利康的新头寸，价值约为 2,072,000 美元。Allworth Financial LP 在第二季度将其在阿斯利康的持股增加了 25.9%。Allworth Financial LP 目前持有 15,850 股该公司的股票，价值 1,108,000 美元，此前在上个季度又购买了 3,264 股。ProShare Advisors LLC 在第二季度将其在阿斯利康的持股增加了 6.1%。ProShare Advisors LLC 目前持有 833,661 股该公司的股票，价值 58,256,000 美元，此前在上个季度又购买了 48,255 股。Profund Advisors LLC 在第二季度将其在阿斯利康的持股增加了 14.8%。Profund Advisors LLC 目前持有 52,952 股该公司的股票，价值 3,700,000 美元，此前在上个季度又购买了 6,814 股。最后，King Luther Capital Management Corp 在第二季度获得了阿斯利康的新头寸，价值 257,000 美元。对冲基金和其他机构投资者持有该公司 20.35% 的股票。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对该公司发布了报告。Jefferies Financial Group 于 10 月 27 日星期一对阿斯利康进行了覆盖，给予该股票 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对阿斯利康股票的 &#34;买入 (b)&#34; 评级。最后，德意志银行在 10 月 16 日星期四的研究报告中将阿斯利康的股票评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。五位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价格为 86.00 美元。</p>
<ul>
<li>Tempus AI 股票：是时候加倍下注还是割肉？</li>
</ul>
<p><strong>查看我们关于阿斯利康的最新报告</strong></p>
<h2>阿斯利康股票表现</h2>
<p>阿斯利康股票在周四开盘价为 87.68 美元。该公司的债务与股本比率为 0.55，速动比率为 0.67，流动比率为 0.86。该公司的市值为 2719.3 亿美元，市盈率为 32.96，市盈增长比率为 1.52，贝塔值为 0.34。阿斯利康的股价在过去一年最低为 61.24 美元，最高为 89.32 美元。该公司的 50 日移动平均价格为 81.85 美元，200 日移动平均价格为 75.95 美元。</p>
<ul>
<li>Cellectis 制定 2025 年计划，受益于阿斯利康交易</li>
</ul>
<p>阿斯利康 (NASDAQ:AZN - 获取免费报告) 最近于 11 月 6 日星期四公布了季度财报。该公司报告每股收益 (EPS) 为 1.19 美元，超出市场共识预期的 1.14 美元，超出 0.05 美元。该公司在本季度的收入为 151.9 亿美元，而分析师预期为 147.5 亿美元。阿斯利康的净利润率为 14.68%，股本回报率为 32.84%。该公司的季度收入较去年同期增长了 12.0%。在去年同期，该公司每股收益为 2.08 美元。卖方分析师预计阿斯利康 PLC 本年度将发布 4.51 美元的每股收益。</p>
<h2>阿斯利康公司简介</h2>
<p>(免费报告)</p>
<p>阿斯利康 PLC 是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票超过阿斯利康</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>随着沃伦·巴菲特接近退出，伯克希尔积累了创纪录的现金</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>稀土股票：并非真正的停火</li>
<li>投资高市盈率增长股</li>
<li>切割利润：感恩节餐桌上的三只食品股票</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AZN 吗？</strong> 访问 HoldingsChannel.com 获取阿斯利康 PLC (NASDAQ:AZN - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿斯利康吗？</h2>
<p>在考虑阿斯利康之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而阿斯利康并不在名单上。</p>
<p>虽然阿斯利康目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿斯利康制药

阿斯利康

<p>Nwam LLC 在第二季度将其在阿斯利康制药的持股减少了 40.1%，目前持有 7,036 股，价值 535,000 美元。其他机构投资者也调整了他们的持仓，其中一些增加了持股。分析师的评级意见不一，普遍认为是 “适度买入”，目标价格为 86 美元。阿斯利康最近的财报超出预期，收入同比增长 12%</p>

<p>Nwam LLC lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 40.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,036 shares of the company's stock after selling 4,720 shares during the period. Nwam LLC's holdings in AstraZeneca were worth $535,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Nwam LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在阿斯利康制药 (NASDAQ:AZN - 免费报告) 的持股减少了 40.1%。该基金在此期间出售了 4,720 股后，持有该公司 7,036 股股票。Nwam LLC 在阿斯利康的持股在最近的报告期末价值为 535,000 美元。</p>
</div><ul>
<li>How Does D-Wave Stack Up Against Quantum Competitors?</li>
</ul>
<div class="lb-trans"><ul>
<li>D-Wave 与量子竞争对手相比如何？</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently modified their holdings of the business. Vise Technologies Inc. purchased a new position in shares of AstraZeneca during the 2nd quarter worth approximately $2,072,000. Allworth Financial LP grew its holdings in AstraZeneca by 25.9% during the 2nd quarter. Allworth Financial LP now owns 15,850 shares of the company's stock valued at $1,108,000 after buying an additional 3,264 shares during the last quarter. ProShare Advisors LLC grew its holdings in AstraZeneca by 6.1% during the 2nd quarter. ProShare Advisors LLC now owns 833,661 shares of the company's stock valued at $58,256,000 after buying an additional 48,255 shares during the last quarter. Profund Advisors LLC increased its position in AstraZeneca by 14.8% during the second quarter. Profund Advisors LLC now owns 52,952 shares of the company's stock worth $3,700,000 after buying an additional 6,814 shares in the last quarter. Finally, King Luther Capital Management Corp acquired a new position in shares of AstraZeneca in the second quarter worth $257,000. Hedge funds and other institutional investors own 20.35% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对该公司的持股。Vise Technologies Inc. 在第二季度购买了阿斯利康的新头寸，价值约为 2,072,000 美元。Allworth Financial LP 在第二季度将其在阿斯利康的持股增加了 25.9%。Allworth Financial LP 目前持有 15,850 股该公司的股票，价值 1,108,000 美元，此前在上个季度又购买了 3,264 股。ProShare Advisors LLC 在第二季度将其在阿斯利康的持股增加了 6.1%。ProShare Advisors LLC 目前持有 833,661 股该公司的股票，价值 58,256,000 美元，此前在上个季度又购买了 48,255 股。Profund Advisors LLC 在第二季度将其在阿斯利康的持股增加了 14.8%。Profund Advisors LLC 目前持有 52,952 股该公司的股票，价值 3,700,000 美元，此前在上个季度又购买了 6,814 股。最后，King Luther Capital Management Corp 在第二季度获得了阿斯利康的新头寸，价值 257,000 美元。对冲基金和其他机构投资者持有该公司 20.35% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have recently issued reports on the company. Jefferies Financial Group assumed coverage on AstraZeneca in a research report on Monday, October 27th. They issued a &#34;buy&#34; rating on the stock. Weiss Ratings reissued a &#34;buy (b)&#34; rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Thursday, October 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $86.00.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发布了报告。Jefferies Financial Group 于 10 月 27 日星期一对阿斯利康进行了覆盖，给予该股票 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对阿斯利康股票的 &#34;买入 (b)&#34; 评级。最后，德意志银行在 10 月 16 日星期四的研究报告中将阿斯利康的股票评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。五位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价格为 86.00 美元。</p>
</div><ul>
<li>Tempus AI Stock: Time to Double Down or Cut and Run?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tempus AI 股票：是时候加倍下注还是割肉？</li>
</ul>
</div><p><strong>Check Out Our Latest Report on AstraZeneca</strong></p>
<div class="lb-trans"><p><strong>查看我们关于阿斯利康的最新报告</strong></p>
</div><h2>AstraZeneca Stock Performance</h2>
<div class="lb-trans"><h2>阿斯利康股票表现</h2>
</div><p>Shares of AZN stock opened at $87.68 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market capitalization of $271.93 billion, a price-to-earnings ratio of 32.96, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a one year low of $61.24 and a one year high of $89.32. The company has a 50 day moving average price of $81.85 and a 200 day moving average price of $75.95.</p>
<div class="lb-trans"><p>阿斯利康股票在周四开盘价为 87.68 美元。该公司的债务与股本比率为 0.55，速动比率为 0.67，流动比率为 0.86。该公司的市值为 2719.3 亿美元，市盈率为 32.96，市盈增长比率为 1.52，贝塔值为 0.34。阿斯利康的股价在过去一年最低为 61.24 美元，最高为 89.32 美元。该公司的 50 日移动平均价格为 81.85 美元，200 日移动平均价格为 75.95 美元。</p>
</div><ul>
<li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>Cellectis 制定 2025 年计划，受益于阿斯利康交易</li>
</ul>
</div><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analysts' expectations of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business's quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.08 EPS. Sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.</p>
<div class="lb-trans"><p>阿斯利康 (NASDAQ:AZN - 获取免费报告) 最近于 11 月 6 日星期四公布了季度财报。该公司报告每股收益 (EPS) 为 1.19 美元，超出市场共识预期的 1.14 美元，超出 0.05 美元。该公司在本季度的收入为 151.9 亿美元，而分析师预期为 147.5 亿美元。阿斯利康的净利润率为 14.68%，股本回报率为 32.84%。该公司的季度收入较去年同期增长了 12.0%。在去年同期，该公司每股收益为 2.08 美元。卖方分析师预计阿斯利康 PLC 本年度将发布 4.51 美元的每股收益。</p>
</div><h2>AstraZeneca Company Profile</h2>
<div class="lb-trans"><h2>阿斯利康公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p>
<div class="lb-trans"><p>阿斯利康 PLC 是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AstraZeneca</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Carving Up Profits: 3 Food Stocks on the Thanksgiving Table</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过阿斯利康</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>随着沃伦·巴菲特接近退出，伯克希尔积累了创纪录的现金</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>稀土股票：并非真正的停火</li>
<li>投资高市盈率增长股</li>
<li>切割利润：感恩节餐桌上的三只食品股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AZN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AZN 吗？</strong> 访问 HoldingsChannel.com 获取阿斯利康 PLC (NASDAQ:AZN - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AZN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿斯利康吗？</h2>
</div><p>Before you consider AstraZeneca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿斯利康之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而阿斯利康并不在名单上。</p>
</div><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿斯利康目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nwam LLC 出售了 AstraZeneca PLC $AZN 的股票